Results 251 to 260 of about 124,855 (301)

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello   +20 more
wiley   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection. [PDF]

open access: yesFront Immunol
Aran A   +8 more
europepmc   +1 more source

Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial). [PDF]

open access: yesJ Immunother Cancer
Nelson A   +13 more
europepmc   +1 more source

Title: AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study. [PDF]

open access: yesCancer Immunol Immunother
Hamada K   +17 more
europepmc   +1 more source

Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs). [PDF]

open access: yesBMC Cancer
Takada K   +8 more
europepmc   +1 more source

Tumor-Infiltrating Lymphocytes

The Cancer Journal, 2015
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2 has shown reproducible objective response rates of approximately 50% in patients with highly advanced, refractory metastatic melanoma.
Michal J, Besser   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy